Jay Luly is President and Chief Executive Officer of Enanta Pharmaceuticals Inc (ENTA). The company reported total compensation of $2,769,548 for fiscal year 2025.
| Salary | $803,300 |
|---|---|
| Bonus | $0 |
| Stock awards | $128,550 |
| Option awards | $1,223,975 |
| Non-equity incentive plan | $591,665 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $22,058 |
| Total | $2,769,548 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Enanta Pharmaceuticals Inc filed January 26, 2026, accession 0001193125-26-022558.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jay Luly this page | President and Chief Executive Officer | $2,769,548 |
| Scott Rottinghaus | Chief Medical Officer | $1,343,212 |
| Yat Sun Or | Chief Scientific Officer | $1,293,790 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Enanta Pharmaceuticals Inc compensation brief.
Jay Luly's compensation sits inside Enanta Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.